 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Asahi Life Asset Management CO. LTD. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 12.5% during the 2nd quarter, according to the company in its...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Asahi Life Asset Management CO. LTD.

Regeneron Pharmaceuticals (NASDAQ:REGN  Get Free Report) had its price target lifted by research analysts at Bank of America from $665.00 to $680.00 in a research note issued to investors on...

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $680.00 at Bank of America

Smithbridge Asset Management Inc. DE cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 1.1% in the second quarter, according to the company in its...

Smithbridge Asset Management Inc. DE Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Murphy Pohlad Asset Management LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 5.2% in the second quarter, according to the company in its most recent...

Murphy Pohlad Asset Management LLC Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also...

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on...

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat...

Dupixent  (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

Smithbridge Asset Management Inc. DE lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 3.3% in the second quarter, according to the company in...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Decreased by Smithbridge Asset Management Inc. DE

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc...

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

Evkeeza is a first-in-class medicine approved by Health Canada, the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultrarare, inherited form of high...

Ultragenyx Launches Evkeeza  (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Watchers	15,515
52-Wk Low	$668.00
52-Wk High	$847.50

Market Cap	$88.8B
Volume (M)	487,684.00
52-Wk High	$847.50
52-Wk Low	$668.00

REGN Regeneron Pharmaceuticals, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals